TORONTO, Dec. 9, 2020 /CNW/ - Fred Ors, CEO, IMV Inc.
(TSX: IMV), shares his company's story in an
interview with TMX Group.
The C-Suite at The Open video interview series highlights the
unique perspectives of listed companies on Toronto Stock Exchange
and TSX Venture Exchange. Videos provide insight into how
company executives think in the current business environment.
To see the latest C-Suite at The Open videos visit
About IMV Inc. (TSX: IMV)
IMV Inc. is a clinical-stage biopharmaceutical company. The
company is engaged in making immunotherapies more effective, more
broadly applicable, and more widely available to people facing
cancer and other serious diseases. Its proprietary drug development
platform provides a patented delivery formulation that enables
controlled and prolonged exposure of antigens to the immune system.
For more information visit: https://www.imv-inc.com/
About TMX Group (TSX: X)
TMX Group's key subsidiaries operate cash and derivative markets
and clearinghouses for multiple asset classes including equities
and fixed income. Toronto Stock Exchange, TSX Venture Exchange, TSX
Alpha Exchange, The Canadian Depository for Securities, Montréal
Exchange, Canadian Derivatives Clearing Corporation,
Trayport and other TMX Group companies provide listing
markets, trading markets, clearing facilities, depository services,
technology solutions, data products and other services to the
global financial community. TMX Group is headquartered in
Toronto and operates offices
across North America (Montréal,
Calgary, Vancouver and New
York), as well as in key international markets including
London, Beijing and Singapore. For more information about TMX
Group, visit our website at www.tmx.com. Follow TMX Group on
SOURCE TMX Group Limited